Werewolf Therapeutics
Werewolf Therapeutics

Werewolf Therapeutics

Biotechnology
WebsiteInvestor RelationsSEC
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

$45.2M

Market Cap • 9/28/2026

2017

(9 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2,8

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,3

EPS

—

Market Cap

Market Cap

45,2M

EV

23,2M

EV/Revenue

0

EV/EBITDA

-0,8

EV/EBIT

-0,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,1%

Total Yield

-0,1%

Payout

0%

Retained Earnings

-485,3M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

5,2%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

-0,4%

CAGR Net Income 5Y

1,7%

CAGR EPS 5Y

-63,1%

CAGR OCF 5Y

1%

Leverage

N.D./EBITDA

0,8

Debt/Equity

0%

Current Ratio

2,9

Quick Ratio

2,8

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium